Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Investigational Ebola Vaccines in Healthy Adults in Uganda
NCT02354404Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2015
- Primary completion
- Apr 2017
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cAd3-EBO, cAd3-EBOV and MVA-EbolaZ in Ebola virus disease (EVD) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Incidence of solicited adverse events after vaccination at 7 days, Incidence of unsolicited adverse events of any severity at 28 days and 2 more. Started Jan 2015; status: completed.
02
Drugs
cAd3-EBOcAd3-EBOVMVA-EbolaZ
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02354404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354404.